| Stereochemistry | RACEMIC |
| Molecular Formula | C25H29N3O3 |
| Molecular Weight | 419.5161 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CCN1C(=O)NC2=C1C=CC=C2)NCC(O)COC3=CC=CC4=C3C=CC=C4
InChI
InChIKey=YWRIUGFSIQMHJK-UHFFFAOYSA-N
InChI=1S/C25H29N3O3/c1-25(2,14-15-28-22-12-6-5-11-21(22)27-24(28)30)26-16-19(29)17-31-23-13-7-9-18-8-3-4-10-20(18)23/h3-13,19,26,29H,14-17H2,1-2H3,(H,27,30)
| Molecular Formula | C25H29N3O3 |
| Molecular Weight | 419.5161 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Adimolol is an antihypertensive agent with a potent antagonist of central beta-adrenoceptors and has a weaker alpha 1-adrenolytic action. The central alpha 2-antagonistic effect is either very weak or absent. The reduction in beta-adrenoceptor number following adimolol suggests that this prolonged effect may not be solely due to competitive antagonism but may additionally depend upon non-competitive antagonism at beta-adrenoceptors. Adimolol reduced supine, standing and exercise heart rates in a dose dependent manner.
